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Reply from the AuthorsTo the Editor: We have a number of concerns with
Dr. Ross and his colleagues raise questions regardingthe report recently published in Kidney International by
the randomized prospective trial of the LifeSite system.Schwab et al [1] of low infection rates in the LifeSite
Hemodialysis Access System. The comparison of two ran- The extension phase of the study used isopropyl alcohol
domized arms, the Tesio-Cath and LifeSite with oxychlor- instead of oxychlorosene as the port sterilant. It extended
osene groups, with a nonrandomized arm, the LifeSite from the initial randomized study and used the catheter
with isopropyl alcohol group, is of dubious validity. group as a retrospective but otherwise identically selected
The infection rate in the Tesio-Cath group was higher control group. The infection rate in the catheter arm (3.3
than reported elsewhere for temporary hemodialysis ac- per 1000 use days) was similar to other nephrology-con-
cess [2]. Four exit-site infections were diagnosed in the ducted prospective studies of hemodialysis catheters (3.9
Tesio-Cath group, versus none in either LifeSite group. to 5.5 per 1000 use days) [1–3]
The criteria for diagnosis of exit-site infection were not The concern that these port devices will perform worse
specified, but apparently did not include a requirement than the prospective trial when patients are selected who
for positive cultures, as one patient with a locally infected have failed all other permanent vascular access is valid.
Tesio-Cath had a negative culture. In the experience of the original Dialyis Outcomes Quality
Schwab et al “suggest that long-term venous access may Initiative (DOQI) panel, patients who failed permanent
be provided by a subcutaneous device.” This may be true, artriovenous access and were dependent on catheter-
but only in selected patients. The LifeSite device is labeled based access had some of the worst long-term outcome
only for use in hemodialysis as a bridge device to perma- of any subset of hemodialysis patients. Whether ports
nent venous access. In a warning letter to Vasca, Inc., the or other techniques will improve these abysmal catheter
Food and Drug Administration (FDA) noted 129 com- outcomes in these patients awaits clinical trials.
plaints of death or serious injury related to the LifeSite As clearly expressed in the study, these port devices
device, many inadequately reported to the FDA by Vasca. require expertise in their placement and training in their
The letter stated that “the majority of reported deaths use. Placement of these devices in non-internal jugular
and many reported injuries occurred in patients who were positions and use by untrained centers should be expected
not candidates for permanent access,” and warned about to have higher complication rates.
the risks of use “in patients with a history of multiple Catheter access for hemodialysis of and by itself is asso-
access failures or access infections, that are catheter de- ciated with substantially increased risk of death and hospi-
pendent for dialysis access, and are not candidates for talization even when other risk factors are controlled [4].
permanent access placement” [3]. Our experience with Development and testing of new venous access devices is
the LifeSite system in chronically ill dialysis patients with essential to improving patient outcomes. Used correctly
previous access failures suggests that subcutaneous de-
we believe hemodialysis access ports represent just such
vices may be much more prone to infection in this popula-
an improvement.tion [4].
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